Posted 6th October 2022 by Nicholas Noakes
Digital health solutions in general have a poor track record of being sustained once they are implemented, often resulting in abandonment of the technology. Current digital pathology and artificial intelligence (AI) deployment strategies are generally too IT-focused – the technology being the focus, rather than the people and environment into which they are being deployed. Furthermore, a focus on technology alone will also hamper the effective integration of AI tools into the diagnostic workflow.
Posted 28th April 2022 by Nicholas Noakes
“Our biggest challenge in this new century is to take an idea that seems abstract – sustainable development – and turn it into a reality ”Kofi Annan
To try and turn that abstract idea into something more tangible, Global Engage has joined ISLA. This is a body that is working with the events industry to accelerate its transition to a sustainable future.
Posted 11th March 2022 by Nicholas Noakes
Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.Prof Alexi Baidoshvili
Posted 10th February 2022 by Nicholas Noakes
As the world considers how it can mitigate climate change, Global Engage has committed to playing its part by reducing the impact of running events. But how to do it? I recently attended an onboarding course organised by ISLA and discovered that “Carbon Neutral” and “Net Zero” are not the same thing!
Posted 10th January 2022 by Nicholas Noakes
It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.
Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology
Posted 30th September 2021 by Nicholas Noakes
“What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.“
Dr Hamid Tizhoosh
Posted 7th September 2021 by Nicholas Noakes
There has been a rapid acceleration of skin microbiome research. Today about 5% of all microbiome clinical studies and 16% of all probiotic products online are dermatology related. Meanwhile, skin probiotics are growing eight times faster than any other probiotic supplement. In clinical cosmetic studies, the microbiome is the fourth largest category.